Clinical utility and cost of non-invasive prenatal testing with cfDNA analysis in high-risk women based on a US population

Ken Song, Thomas J. Musci, Aaron Caughey

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Objective: Evaluate the clinical and economic consequences of fetal trisomy 21 (T21) screening with non-invasive prenatal testing (NIPT) in high-risk pregnant women. Methods: Using a decision-analytic model, we estimated the number of T21 cases detected, the number of invasive procedures performed, corresponding euploid fetal losses and total costs for three screening strategies: first trimester combined screening (FTS), integrated screening (INT) or NIPT, whereby NIPT was performed in high-risk patients (women 35 years or older or women with a positive conventional screening test). Modeling was based on a 4 million pregnant women cohort in the US. Results: NIPT, at a base case price of $795, was more clinically effective and less costly (dominant) over both FTS and INT. NIPT detected 4823 T21 cases based on 5330 invasive procedures. FTS detected 3364 T21 cases based on 108th364 procedures and INT detected 3760 cases based on 108th760 procedures. NIPT detected 28% and 43% more T21 cases compared to INT and FTS, respectively, while reducing invasive procedures by >95% and reducing euploid fetal losses by >99%. Total costs were $3786M with FTS, $3919M with INT and $3403M with NIPT. Conclusions: NIPT leads to improved T21 detection and reduction in euploid fetal loss at lower total healthcare expenditures.

Original languageEnglish (US)
Pages (from-to)1180-1185
Number of pages6
JournalJournal of Maternal-Fetal and Neonatal Medicine
Volume26
Issue number12
DOIs
StatePublished - Aug 2013

Fingerprint

Down Syndrome
First Pregnancy Trimester
Costs and Cost Analysis
Population
Pregnant Women
Health Expenditures
Economics
Delivery of Health Care

Keywords

  • Aneuploidy screening
  • Cell-free DNA
  • Cost-effectiveness
  • Down syndrome
  • Non-invasive prenatal testing
  • Trisomy 21

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Cite this

Clinical utility and cost of non-invasive prenatal testing with cfDNA analysis in high-risk women based on a US population. / Song, Ken; Musci, Thomas J.; Caughey, Aaron.

In: Journal of Maternal-Fetal and Neonatal Medicine, Vol. 26, No. 12, 08.2013, p. 1180-1185.

Research output: Contribution to journalArticle

@article{3c64c87ed9a249a9b64840a4fc99f867,
title = "Clinical utility and cost of non-invasive prenatal testing with cfDNA analysis in high-risk women based on a US population",
abstract = "Objective: Evaluate the clinical and economic consequences of fetal trisomy 21 (T21) screening with non-invasive prenatal testing (NIPT) in high-risk pregnant women. Methods: Using a decision-analytic model, we estimated the number of T21 cases detected, the number of invasive procedures performed, corresponding euploid fetal losses and total costs for three screening strategies: first trimester combined screening (FTS), integrated screening (INT) or NIPT, whereby NIPT was performed in high-risk patients (women 35 years or older or women with a positive conventional screening test). Modeling was based on a 4 million pregnant women cohort in the US. Results: NIPT, at a base case price of $795, was more clinically effective and less costly (dominant) over both FTS and INT. NIPT detected 4823 T21 cases based on 5330 invasive procedures. FTS detected 3364 T21 cases based on 108th364 procedures and INT detected 3760 cases based on 108th760 procedures. NIPT detected 28{\%} and 43{\%} more T21 cases compared to INT and FTS, respectively, while reducing invasive procedures by >95{\%} and reducing euploid fetal losses by >99{\%}. Total costs were $3786M with FTS, $3919M with INT and $3403M with NIPT. Conclusions: NIPT leads to improved T21 detection and reduction in euploid fetal loss at lower total healthcare expenditures.",
keywords = "Aneuploidy screening, Cell-free DNA, Cost-effectiveness, Down syndrome, Non-invasive prenatal testing, Trisomy 21",
author = "Ken Song and Musci, {Thomas J.} and Aaron Caughey",
year = "2013",
month = "8",
doi = "10.3109/14767058.2013.770464",
language = "English (US)",
volume = "26",
pages = "1180--1185",
journal = "Journal of Maternal-Fetal and Neonatal Medicine",
issn = "1476-7058",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Clinical utility and cost of non-invasive prenatal testing with cfDNA analysis in high-risk women based on a US population

AU - Song, Ken

AU - Musci, Thomas J.

AU - Caughey, Aaron

PY - 2013/8

Y1 - 2013/8

N2 - Objective: Evaluate the clinical and economic consequences of fetal trisomy 21 (T21) screening with non-invasive prenatal testing (NIPT) in high-risk pregnant women. Methods: Using a decision-analytic model, we estimated the number of T21 cases detected, the number of invasive procedures performed, corresponding euploid fetal losses and total costs for three screening strategies: first trimester combined screening (FTS), integrated screening (INT) or NIPT, whereby NIPT was performed in high-risk patients (women 35 years or older or women with a positive conventional screening test). Modeling was based on a 4 million pregnant women cohort in the US. Results: NIPT, at a base case price of $795, was more clinically effective and less costly (dominant) over both FTS and INT. NIPT detected 4823 T21 cases based on 5330 invasive procedures. FTS detected 3364 T21 cases based on 108th364 procedures and INT detected 3760 cases based on 108th760 procedures. NIPT detected 28% and 43% more T21 cases compared to INT and FTS, respectively, while reducing invasive procedures by >95% and reducing euploid fetal losses by >99%. Total costs were $3786M with FTS, $3919M with INT and $3403M with NIPT. Conclusions: NIPT leads to improved T21 detection and reduction in euploid fetal loss at lower total healthcare expenditures.

AB - Objective: Evaluate the clinical and economic consequences of fetal trisomy 21 (T21) screening with non-invasive prenatal testing (NIPT) in high-risk pregnant women. Methods: Using a decision-analytic model, we estimated the number of T21 cases detected, the number of invasive procedures performed, corresponding euploid fetal losses and total costs for three screening strategies: first trimester combined screening (FTS), integrated screening (INT) or NIPT, whereby NIPT was performed in high-risk patients (women 35 years or older or women with a positive conventional screening test). Modeling was based on a 4 million pregnant women cohort in the US. Results: NIPT, at a base case price of $795, was more clinically effective and less costly (dominant) over both FTS and INT. NIPT detected 4823 T21 cases based on 5330 invasive procedures. FTS detected 3364 T21 cases based on 108th364 procedures and INT detected 3760 cases based on 108th760 procedures. NIPT detected 28% and 43% more T21 cases compared to INT and FTS, respectively, while reducing invasive procedures by >95% and reducing euploid fetal losses by >99%. Total costs were $3786M with FTS, $3919M with INT and $3403M with NIPT. Conclusions: NIPT leads to improved T21 detection and reduction in euploid fetal loss at lower total healthcare expenditures.

KW - Aneuploidy screening

KW - Cell-free DNA

KW - Cost-effectiveness

KW - Down syndrome

KW - Non-invasive prenatal testing

KW - Trisomy 21

UR - http://www.scopus.com/inward/record.url?scp=84880304596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880304596&partnerID=8YFLogxK

U2 - 10.3109/14767058.2013.770464

DO - 10.3109/14767058.2013.770464

M3 - Article

C2 - 23356557

AN - SCOPUS:84880304596

VL - 26

SP - 1180

EP - 1185

JO - Journal of Maternal-Fetal and Neonatal Medicine

JF - Journal of Maternal-Fetal and Neonatal Medicine

SN - 1476-7058

IS - 12

ER -